North America Insulin Delivery Devices Market By Product Type (Insulin Pens {Reusable Insulin Pens and Disposable Insulin Pens}, Insulin Pumps {Patch Pumps and Tethered Pumps}, Insulin Pen Needles {Standard Pen Needles and Safety Pen Needles}, Insulin Syringes, and Other Products), By Application (Type I Diabetes, Type II Diabetes, and Gestational Diabetes), By End-User (Hospitals & Clinics, Homecare, and Others), Regional Market Size, Segmental analysis, Country Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The North American Insulin Delivery Devices market accounted for USD 7.25 Billion in 2024 and is expected to reach USD 16.1 Billion by 2035, growing at a CAGR of around 7.5% between 2025 and 2035. The North American insulin delivery devices market is comprised of products that are utilized for delivering insulin to diabetic patients, such as insulin pens, syringes, and insulin pumps. Many people suffer from diabetes, especially type 2 diabetes, hence the call for an effective and easier way of administering the insulin delivery system. Products that include smart insulin pens and CGMS are improving patient compliance and glycemic regulation. Contraceptive users in the market are motivated by technological innovation, raising awareness of diabetes care, and a growing aging population.

Report Scope:

Market Dynamics

Government initiatives support improved access to insulin therapies nationwide.

The North American insulin delivery devices market is driven by the growth of diabetes, especially type 1 and type 2. Growing government interest in enhancing access to insulin and related diabetes treatment helps drive market growth as more sufferers obtain needed treatments. Furthermore, innovative insulin pens and bolus device standards improve the patient’s comfort. Rising awareness regarding diabetes and its approach to management will drive market growth. Moreover, greater healthcare spending on diabetes and insurance acceptance of insulin delivery systems contribute to the penetration of enhanced insulin delivery devices.

Pharmaceutical companies, healthcare providers, and tech firms work together for new and relevant technologies so consumers get better solutions and interfaces. The changes in population demographics, like a growing aging population, increase the need for effective insulin delivery, taking the market to new heights.

Increased awareness promotes effective diabetes management and insulin usage.

The driving forces for the North American insulin delivery devices market are the increasing incidence of diabetes, product innovation, and improvement in patient consciousness levels. Currently, the Centers for Disease Control and Prevention (CDC) estimate that 34.2 million people in the US are suffering from diabetes, and there is a definitive need for an insulin delivery system. Smart insulin pens and insulin pumps are a few innovations that make it easier and more precise to provide the correct dose to increase patient compliance. Moreover, the various educational programs and initiatives to create diabetes management awareness play a vital role in the market growth. To improve the use of insulin delivery devices and general health in people under insulin management, a greater awareness of the underlying condition and relevant interventions is essential.

High costs deter patients from adopting advanced delivery devices.

The high cost of advanced delivery technologies emerged as a major threat in the North American insulin delivery devices market. Few patients with limited health insurance can't afford insulin pumps and continuous glucose monitoring systems. This financial constraint may result in the use of conventional techniques that may not emphasize the best glycaemic control. Moreover, while these devices require high investment, with the cost of consumables and maintenance, patients cannot afford to replace them, so they stick to inferior devices. Consequently, economic factors may stifle the market’s overall growth opportunity and exclude a significant portion of the diabetic population.

Wearable technology growth offers new integrated delivery system opportunities.

Wearable technology is a rapidly emerging market with great potential for the North American insulin delivery device market. With diabetes progressing to be a major health issue, the need for improved and easier systems to support patient care is quickly gaining prominence. Insulin pumps and continuous glucose monitors are becoming increasingly sophisticated in real-time data sharing, BG predictions, closed-loop systems, and communicating with a smartphone. This integration increases patients’ compliance with medication doses and gives an understanding of further treatment. Furthermore, the increasing use of telehealth and remote monitoring increases the possibility of these devices improving patients’ care by decreasing healthcare spending. Technology mobility is likely to increase and create a greater market potential since there is increasing demand for the efficient management of diabetes.

Industry Experts Opinion

“A challenging aspect of living with diabetes is counting carbohydrates and dosing the right amount of insulin before consuming snacks and meals. Many people underestimate their carbs, which can lead to high blood sugar (hyperglycemia). Prolonged hyperglycemia can lead to serious health problems impacting the eyes, major organs, and even cognitive function, which is particularly concerning in developing children,"

• Robert Vigersky, M.D., Chief Medical Officer, Medtronic Diabetes, Professor of Medicine, Uniformed Services University of the Health Sciences.

"A lot can happen to blood sugars in the span of an hour or even just a few minutes, so we've designed our system for real life – the algorithm adapts to the user and helps compensate for everyday challenges that are quite common around mealtimes. We built in features informed by extensive customer feedback and we're excited to deliver a system with ease of use at the forefront."

• Que Dallara, EVP and President of Medtronic Diabetes.

Segment Analysis

Based on the product type, the North America Insulin Delivery Devices Market is classified into Insulin Pens, Insulin Pumps, Insulin Pen Needles, Insulin Syringes, and Other Products. Insulin Pens are dominant in the product type segment of North American insulin Delivery Devices Market. Reasons for the popularity of delivery systems include ease of use, compactness, and the capability to produce precise portion sizes for diabetic patients who need periodic insulin injections.

Pre-filled insulin pens and the reusable type encourage more patient compliance because they are easy to use as compared to syringes. Furthermore, historic product improvements such as smart pens deliver the right dosage at the correct time and contribute to their market strength. Because diabetes mellitus is an increasingly widespread disease, the need for effective and convenient insulin administration systems strengthens the leading position of insulin pens in this market.

Based on the application, the North American insulin Delivery Devices Market is classified into Type I Diabetes, Type II Diabetes, and Gestational Diabetes. The largest segment currently extant in the North American insulin delivery devices market is Type II diabetes. The reason for this is increased cases of Type II diabetes, especially caused by rising obesity levels and meal-less lifestyle.

Development in smart pens, continuous glucose monitoring, and increased consciousness about disease management among people add to the growth of this segment. Further, increased availability, accessibility, and easy-to-use devices among the type II diabetes population led to a growth market. Overall, Type II diabetes stands as the largest market segment due to observed trends in global diseases and improvements in diabetes management.

Regional Analysis

The North American insulin delivery devices market exhibits important regional differences based on factors such as the incidence of diabetes, the state of the healthcare system, and preferences. With rising cases of obesity and diabetes in the United States, especially in Midwestern and Southern states, there is a higher consumer base for insulin pumps and pens. The market is propped up by late healthcare standards in urban centers, enabling the adoption of new technologies.

Smart insulin pens and automated distribution systems are examples of recent device designs that are popular in New York and California. Furthermore, emphasis on telehealth and remote monitoring solutions is an emerging trend that gives a changing touch to diabetes management across different demographics. The combination of health needs and technological and economic factors in the region influences the progression of the insulin delivery system in North America.

The North America insulin delivery devices market in Canada is quite distinct due to differences in demography, availability of healthcare infrastructure, and necessity of the products. Some of the largest metropolitan areas, including Toronto and Vancouver, have a consistently higher diabetes rate and need sophisticated insulin delivery products, like insulin pumps and smart pens. It also emphasizes how rural populations suffer and adopt conventional approaches because they do not have access to appropriate specialty therapy.

The general market structure is determined by the policies of certain regions, like Alberta and Ontario, recognized for having significant expenditures in the diabetes care market. The rise of technical advancements like continuous glucose monitoring systems influences the market direction and guarantees Canadians to manage their diabetes in the region’s most appropriate for their needs.

Competitive Landscape

Key players in the North American insulin delivery devices market are focused on new developments and partnerships such as Insulet Corporation, Tandem Diabetes Care, and Medtronic. Consumers favor Insulet's OmniPod 5 due to its simplified SGM integrated system and automated insulin delivery functions. It has improved tremendously with its tX2 insulin pump, making it possible to be connected and to have software compatibility. Further, Xeris Pharmaceuticals has also developed the Gvoke glucagon injection, improving hypoglycemia control. Becton, Dickinson, and Company (BD) enhancing their insulin pen innovation. This environment dynamics is evidenced by increasing partnerships to connect digital health solutions and provide a broad view of personalized diabetes care. The market is dynamic and growing due to the advancement of technology and the patient's demands for effective and comfortable insulin delivery systems.

North America Insulin Delivery Devices Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In August 2024, the FDA cleared the Omnipod® 5 Automated Insulin Delivery System for use in individuals with Type 2 diabetes. This approval expanded access to advanced insulin management technology, offering a more convenient option for those managing their diabetes. The system automated insulin delivery, enhancing patient care and improving glycemic control.
• In May 2024, Tandem Diabetes Care, Inc. and Dexcom, Inc. announced that the Tandem Mobi insulin pump with Control-IQ technology became fully compatible with the Dexcom G7 and G6 Continuous Glucose Monitoring (CGM) Systems. Launched earlier that year in the US, the Tandem Mobi was the smallest and most robust automated insulin delivery (AID) device in the world.

Report Coverage:

By Product Type

• Insulin Pens
  • Reusable Insulin Pens
  • Disposable Insulin Pens
• Insulin Pumps
  • Patch Pumps
  • Tethered Pumps
• Insulin Pen Needles
  • Standard Pen Needles
  • Safety Pen Needles
• Insulin Syringes
• Other Products

By Application

• Type I Diabetes
• Type II Diabetes
• Gestational Diabetes

By End-User

• Hospitals & Clinics
• Homecare
• Others

By Region

North America

• U.S.
• Canada

List of Companies:

• Insulet Corporation
• Tandem Diabetes Care
• Becton, Dickinson and Company
• Xeris Pharmaceuticals
• Zynx Health
• CeQur
• AstraZeneca
• Cala Health
• Medtronic MiniMed
• Tandem Diabetes Care
• Apex Medical
• InPen
• DreaMed Diabetes
• Senseonics
• Glooko

Frequently Asked Questions (FAQs)

---

Related Report